DK0740650T3 - Codrugs som metode til styret transport af lægemiddel - Google Patents

Codrugs som metode til styret transport af lægemiddel

Info

Publication number
DK0740650T3
DK0740650T3 DK94909643T DK94909643T DK0740650T3 DK 0740650 T3 DK0740650 T3 DK 0740650T3 DK 94909643 T DK94909643 T DK 94909643T DK 94909643 T DK94909643 T DK 94909643T DK 0740650 T3 DK0740650 T3 DK 0740650T3
Authority
DK
Denmark
Prior art keywords
codrug
codrugs
controlled drug
drug transport
composition
Prior art date
Application number
DK94909643T
Other languages
English (en)
Inventor
Guo Hong
Grazyna Cynkowska
Paul Ashton
Peter Anthony Crooks
Robert Mack Riggs
Tadeusz Cynkowski
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Application granted granted Critical
Publication of DK0740650T3 publication Critical patent/DK0740650T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/101,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Paper (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)
DK94909643T 1994-01-28 1994-02-17 Codrugs som metode til styret transport af lægemiddel DK0740650T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18746294A 1994-01-28 1994-01-28

Publications (1)

Publication Number Publication Date
DK0740650T3 true DK0740650T3 (da) 2004-09-27

Family

ID=22689099

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94909643T DK0740650T3 (da) 1994-01-28 1994-02-17 Codrugs som metode til styret transport af lægemiddel

Country Status (10)

Country Link
EP (1) EP0740650B1 (da)
JP (1) JP4039683B2 (da)
AT (1) ATE267798T1 (da)
AU (1) AU705226B2 (da)
CA (1) CA2182228C (da)
DE (1) DE69433818T2 (da)
DK (1) DK0740650T3 (da)
ES (1) ES2222455T3 (da)
PT (1) PT740650E (da)
WO (1) WO1995020567A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
AU740264C (en) * 1997-09-11 2002-06-06 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
JPH11171768A (ja) * 1997-10-15 1999-06-29 Taisho Pharmaceut Co Ltd 消炎鎮痛外用剤
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6762182B1 (en) 1999-01-07 2004-07-13 Vanderbilt University Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6624317B1 (en) 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
FR2818908B1 (fr) * 2000-12-29 2004-04-02 Dospharma Utilisation en tant que medicament d'un compose restituant in vivo des principes actifs
CN1520297A (zh) * 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统
IN2014DN10834A (da) * 2001-09-17 2015-09-04 Psivida Inc
MXPA04006875A (es) * 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003070745A2 (en) 2002-02-20 2003-08-28 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
CN1658836A (zh) * 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1633403A2 (en) * 2003-05-21 2006-03-15 Control Delivery Systems, Inc. Codrugs of diclofenac
FR2867189A1 (fr) * 2004-03-08 2005-09-09 Ludovic Bourre Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase
JP2007534702A (ja) 2004-04-26 2007-11-29 バンダービルト・ユニバーシティ 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
JP2008535928A (ja) * 2005-04-12 2008-09-04 シヴィダ・インコーポレイテッド HMGCoA還元酵素インヒビターの組合せ及びその使用
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
WO2007149456A2 (en) 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
US8883809B2 (en) 2008-11-19 2014-11-11 Council Of Scientific & Industrial Research Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof
EP3078377A3 (en) 2009-05-12 2017-04-05 Romark Laboratories, L.C. Nitazoxanide and tizoxanide as anti-viral agents
MX341877B (es) 2009-06-26 2016-09-06 Romark Laboratories L C * Compuestos y métodos para tratar influenza.
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9346803B2 (en) 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
CN105025929A (zh) 2013-03-08 2015-11-04 阿勒根公司 环孢菌素a-类固醇缀合物
US9402912B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
CN103588713B (zh) * 2013-06-07 2014-09-17 潍坊博创国际生物医药研究院 多靶点型乌苯美司前药衍生物及其制备方法和用途
WO2015027018A1 (en) * 2013-08-21 2015-02-26 Senseonics, Incorporated Drug elution for in vivo protection of bio-sensing analytes
WO2019148294A1 (en) * 2018-02-02 2019-08-08 Interface Biologics, Inc. Dimeric dexamethasone prodrug compositions and uses thereof
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
EP3986388A4 (en) * 2019-06-24 2024-02-21 Diverse Biotech, Inc. CANNABINOID CONJUGATE MOLECULES
CN114599406A (zh) * 2019-07-10 2022-06-07 波纹疗法公司 包含二聚类固醇前药的表面涂层和可植入装置及其用途
JP2022541341A (ja) * 2019-07-25 2022-09-22 リップル セラピューティクス コーポレーション ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
US20250057962A1 (en) * 2021-11-03 2025-02-20 Ripple Therapeutics Corporation Processable compositions and use for the same
US11883499B2 (en) 2022-02-01 2024-01-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
US11660348B1 (en) 2022-02-01 2023-05-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
US5157151A (en) * 1990-12-18 1992-10-20 Isaac Angres Salts of 1-adamantamine and formulations thereof
WO1994029327A1 (en) * 1993-06-07 1994-12-22 British Technology Group Limited Anticancer compounds

Also Published As

Publication number Publication date
CA2182228C (en) 2008-09-16
PT740650E (pt) 2004-10-29
EP0740650A4 (en) 2000-04-19
AU705226B2 (en) 1999-05-20
ATE267798T1 (de) 2004-06-15
EP0740650B1 (en) 2004-05-26
CA2182228A1 (en) 1995-08-03
JPH09509151A (ja) 1997-09-16
DE69433818D1 (de) 2004-07-01
WO1995020567A1 (en) 1995-08-03
DE69433818T2 (de) 2005-06-16
ES2222455T3 (es) 2005-02-01
EP0740650A1 (en) 1996-11-06
AU6254594A (en) 1995-08-15
JP4039683B2 (ja) 2008-01-30

Similar Documents

Publication Publication Date Title
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
GB9907571D0 (en) Compounds
ATE390124T1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
SE9800905D0 (sv) New therapy in glomerulonephritis
FR2725718B1 (fr) Bis-2-aminopyridines, leur procede de preparation et leurs applications
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
SE9902742D0 (sv) New pharmaceutical formultion
SE0203817D0 (sv) New composition
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung